产品名称
2-硝酸异山梨酯, European Pharmacopoeia (EP) Reference Standard
SMILES string
[N+](=O)([O-])O[C@@H]1[C@H]2OC[C@H]([C@H]2OC1)O
InChI
1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5-,6-/m1/s1
InChI key
YWXYYJSYQOXTPL-JGWLITMVSA-N
grade
pharmaceutical primary standard
API family
isosorbide
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
正在寻找类似产品? 访问 产品对比指南
Application
Isosorbide 2-nitrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
T Murakawa et al.
Masui. The Japanese journal of anesthesiology, 42(2), 225-232 (1993-02-01)
Nineteen patients with ischemic heart disease were studied to determine plasma levels of isosorbide dinitrate (ISDN) and its metabolites, isosorbide-2-mononitrate (2-ISMN) and isosorbide-5-mononitrate (5-ISMN) for 6 hrs during intravenous administration of ISDN, using gas chromatography. Differences in plasma levels of
W Schneider et al.
European journal of clinical pharmacology, 38(2), 145-147 (1990-01-01)
The concentrations of isosorbide dinitrate (ISDN), isosorbide-5-mononitrate (IS-5-MN) and isosorbide-2-mononitrate (IS-2-MN) were determined in plasma (PL), saphenous vein wall (SV) and pectoral muscle (PM) from 8 patients undergoing coronary bypass surgery. The patients were pretreated for 2 days with ISDN
V Hutt et al.
Arzneimittel-Forschung, 43(8), 842-846 (1993-08-01)
In the course of this study the bioavailability and pharmacokinetic profile of a newly developed 2.5 mg (per valve release) oral isosorbide dinitrate (ISDN, CAS 87-33-2) spray preparation (Isoket Spray) were determined and compared with the results for an already
D Smith et al.
Drug metabolism and disposition: the biological fate of chemicals, 18(4), 429-434 (1990-07-01)
A pharmacokinetic model is proposed to describe the plasma levels of isosorbidedinitrate (ISDN) and its two pharmacologically active metabolites, isosorbide-2-mononitrate (IS-2MN) and isosorbide-5-mononitrate (IS-5MN), following the oral administration of several 20-mg sustained release formulations of ISDN. Absorption of ISDN from
N Mukerjee et al.
The Journal of biological chemistry, 269(34), 21664-21669 (1994-08-26)
Isosorbide dinitrate inactivated E1 and E2 isozymes of human aldehyde dehydrogenase (EC 1.2.1.3), abolishing both dehydrogenase and esterase activities. NAD promoted, whereas chloral and NAD protected the enzyme from inactivation. The inactivation was irreversible upon dialysis and occurred without incorporation
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持